18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

OBJECTIVE: The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could sig...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Vandenberghe, R, Van Laere, K, Ivanoiu, A, Salmon, E, Bastin, C, Triau, E, Hasselbalch, S, Law, I, Andersen, A, Korner, A, Minthon, L, Garraux, G, Nelissen, N, Bormans, G, Buckley, C, Owenius, R, Thurfjell, L, Farrar, G, Brooks, D
Formato:	Journal article
Idioma:	English
Publicado em:	2010

Registros relacionados

Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.
por: Vandenberghe, R, et al.
Publicado em: (2013)

Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.
por: Nelissen, N, et al.
Publicado em: (2009)

Longitudinal changes in 18F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations
por: Emma S. Luckett, et al.
Publicado em: (2023-01-01)

Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment
por: Hugh G. Pemberton, et al.
Publicado em: (2023-05-01)

Abeta amyloid deposition in the language system and how the brain responds.
por: Nelissen, N, et al.
Publicado em: (2007)

Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods
por: Mark R. Battle, et al.
Publicado em: (2018-12-01)

Establishing cutoff values for visual amyloid positivity in [18F]flutemetamol PET
por: Yong-Jin Park, et al.
Publicado em: (2025-01-01)

Amyloid-Targeting PET Tracer [18F]Flutemetamol Accumulates in Atherosclerotic Plaques
por: Sanna Hellberg, et al.
Publicado em: (2019-03-01)

Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET
por: Si Eun Kim, et al.
Publicado em: (2020-01-01)

Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Lyduine E. Collij, et al.
Publicado em: (2023-11-01)

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result
por: Westwood, S, et al.
Publicado em: (2018)

Author Correction: Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments
por: Soo Hyun Cho, et al.
Publicado em: (2021-03-01)

Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging.
por: Koole, M, et al.
Publicado em: (2009)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
por: Sarah Westwood, et al.
Publicado em: (2018-12-01)

In vivo amyloid imaging in cortical superficial siderosis.
por: Dhollander, I, et al.
Publicado em: (2011)

Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
por: Milos D. Ikonomovic, et al.
Publicado em: (2018-06-01)

Longitudinal Assessment of Amyloid-β Deposition by [18F]-Flutemetamol PET Imaging Compared With [11C]-PIB Across the Spectrum of Alzheimer’s Disease
por: Shizuo Hatashita, et al.
Publicado em: (2019-09-01)

Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents 18F-flutemetamol and 18F-florbetaben
por: Hye Joo Son, et al.
Publicado em: (2018-07-01)

Functional Changes in the Language Network in Response to Increased Amyloid β Deposition in Cognitively Intact Older Adults.
por: Adamczuk, K, et al.
Publicado em: (2014)

Anatomical based reconstruction of dynamic brain PET images using N-[11C]-methylpiperidin-4-YL-proprionate ([11C]-PMP) in elderly normals
por: Nelissen, N, et al.
Publicado em: (2007)

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
por: Fiona Heeman, et al.
Publicado em: (2019-03-01)

Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated
por: Young-Sil An, et al.
Publicado em: (2021-06-01)

Temporal and anatomical distribution of 18F-flutemetamol uptake in canine brain using positron emission tomography
por: Taesik Yun, et al.
Publicado em: (2020-01-01)

Comparison of [18F]Flutemetamol and [11C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals
por: Val J. Lowe, et al.
Publicado em: (2017-01-01)

Automatic lesion detection and segmentation in 18F-flutemetamol positron emission tomography images using deep learning
por: Chan Ju Ryu
Publicado em: (2022-12-01)

A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.
por: Nordberg, A, et al.
Publicado em: (2013)

Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects
por: James M. Mountz, et al.
Publicado em: (2015-01-01)

18F-flutemetamol PET/CT imaging in the diagnosis of mild cognitive impairment and Alzheimer's disease：a preliminary study
por: LEI Zhe, et al.
Publicado em: (2022-07-01)

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study
por: Hiroshi Matsuda, et al.
Publicado em: (2021-01-01)

Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein E ε4 carriers.
por: Adamczuk, K, et al.
Publicado em: (2013)

Computed Tomography Density and β-Amyloid Deposition of Intraorbital Optic Nerve May Assist in Diagnosing Mild Cognitive Impairment and Alzheimer’s Disease: A 18F-Flutemetamol Positron Emission Tomography/Computed Tomography Study
por: Han Wu, et al.
Publicado em: (2022-03-01)

Cholinergic depletion and basal forebrain volume in primary progressive aphasia
por: Jolien Schaeverbeke, et al.
Publicado em: (2017-01-01)

Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
por: Dietmar Rudolf Thal, et al.
Publicado em: (2019-11-01)

Correction to: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
por: Dietmar Rudolf Thal, et al.
Publicado em: (2020-08-01)

Drug development in Alzheimer’s disease: the contribution of PET and SPECT
por: Lieven Denis Herwig Declercq, et al.
Publicado em: (2016-03-01)

Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults
por: Emma S. Luckett, et al.
Publicado em: (2023-07-01)

Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases
por: Elin Lindström, et al.
Publicado em: (2020-01-01)

Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults
por: Emma S. Luckett, et al.
Publicado em: (2022-09-01)

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease.
por: Nina Schultz, et al.
Publicado em: (2019-01-01)

3D shape perception in posterior cortical atrophy: a visual neuroscience perspective
por: Gillebert, C, et al.
Publicado em: (2015)